# Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

> **NCT00424892** · PHASE2,PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 600 (—)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Desvenlafaxine Sustained Release

## Key facts

- **NCT ID:** NCT00424892
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 600 (—)
- **Last updated:** 2007-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424892, "Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00424892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*